Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Epithelial sodium channel blockers
8 evidence topics · 6 sources
Amiloride when mineralocorticoid receptor antagonists are not tolerated: 2025 AHA/ACC guideline
Amiloride as an alternative to spironolactone: 2024 ESC guideline
Amiloride dosing and availability: 2023 ESH guideline
Amiloride open-label runout: PATHWAY-2 mechanisms substudy
“assessed the effect of amiloride 10–20 mg once daily on clinic systolic blood pressure during an optional 6–12 week open-label runout phase (substudy 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Amiloride (10 mg once daily) reduced clinic systolic blood pressure by 20·4 mm Hg (95% CI 18·3–22·5), compared with a reduction of 18·3 mm Hg (16·2–20·5) with spironolactone (25 mg once daily). No serious adverse events were recorded, and adverse symptoms were not systematically recorded after the end of the double-blind treatment. Mean plasma potassium concentrations increased from 4·02 mmol/L (95% CI 3·95–4·08) on placebo to 4·50 (4·44–4·57) on amiloride (p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amiloride versus spironolactone: randomized noninferiority trial
“Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, mean home SBP measurements were changed from baseline by −13.6 (SD, 8.6) mm Hg and −14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, −0.68 mm Hg; 90% CI, −3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amiloride trial limitations: dose and kidney function
“First, we did not compare the efficacy of higher doses of spironolactone (50 mg vs 20 mg), as used in the PATHWAY-2 trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, we excluded participants with an estimated glomerular filtration rate of less than 50 mL/min/1.73 m2; hence, our results may not be generalizable to patients with chronic kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote